SER 287

Drug Profile

SER 287

Alternative Names: SER-287

Latest Information Update: 09 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Seres Therapeutics
  • Class Anti-inflammatories; Antibacterials; Bacteria
  • Mechanism of Action Bacteria replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Ulcerative colitis

Most Recent Events

  • 05 Jun 2017 Seres Therapeutics completes enrolment in its phase Ib trial for Ulcerative colitis (Second-line therapy or greater) in USA
  • 04 May 2016 Seres Therapeutics enters into research collaboration with the Research Institute of St. Joseph's Hamilton and the Medical University of Graz to develop microbiome-based therapeutics for Inflammatory bowel disease
  • 11 Jan 2016 SER 287 licensed to Nestle Health Science in the World excluding USA and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top